ResMed Inc.
Financials
Valuation Metrics
ResMed Inc.'s Market Cap is $32.64B. At end of 2025 it was $35.20B. Ranked #432 of 3,121 in US market (top 14%), #306 of 1,658 on NYSE (top 18%), #27 of 205 in Health Care Equipment & Services (top 13%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $32.64B | US#432/3,121 Sec#27/205 |
| Revenue | $5.65B | US#825/3,121 Sec#48/205 |
| Net Income | $1.52B | US#409/3,121 Sec#19/205 |
| Total Assets | $8.97B | US#1,052/3,121 Sec#50/205 |
| Net Assets | $6.59B | US#578/3,121 Sec#34/205 |
| Employees | 11,370 | US#805/3,121 Sec#60/205 |
| Value | ||
| P/E | 21.43x | US#1,241/3,121 Sec#31/205 |
| P/B | 4.96x | US#2,230/3,121 Sec#136/205 |
| PEG | 2.45x | US#1,095/3,121 Sec#56/205 |
| P/S | 5.77x | US#2,415/3,121 Sec#157/205 |
| EV/EBITDA | 14.91x | US#1,553/3,121 Sec#61/205 |
| FCF Yield | 8.85% | US#754/3,121 Sec#31/205 |
| Profitability | ||
| ROE | 23.13% | US#468/3,121 Sec#24/205 |
| ROA | 16.99% | US#169/3,121 Sec#8/205 |
| Op. Margin | 33.48% | US#432/3,121 Sec#5/205 |
| Revenue Growth | 9.85% | US#1,289/3,121 Sec#87/205 |
| Earnings Growth | 8.75% | US#1,113/3,121 Sec#61/205 |
| Financial Health | ||
| Debt Ratio | 36.15% | US#412/3,121 Sec#43/205 |
| Total Debt | $826M | US#1,640/3,121 Sec#88/205 |
| FCF | $2.89B | US#281/3,121 Sec#19/205 |
| Cash | $1.47B | US#538/3,121 Sec#29/205 |
| Current Ratio | 3.10x | US#763/3,121 Sec#75/205 |
| Net Debt/EBITDA | -0.30x | US#461/3,121 Sec#36/205 |
| Dividend | ||
| Div. Yield | 1.07% | US#1,291/3,121 Sec#27/205 |
| Div. Growth | 10.34% | US#491/3,121 Sec#15/205 |
| Performance | ||
| 1Y Return | -17.27% | US#2,280/3,121 Sec#153/205 |
| 1M Return | -2.44% | US#566/3,121 Sec#68/205 |
| From 52W High | -20.63% | US#1,464/3,121 Sec#102/205 |
| 1Y MDD | -35.16% | US#1,746/3,121 Sec#93/205 |
| Trading | ||
| Volume | 1,238,670 shares | US#1,578/3,121 Sec#96/205 |
| Trading Value | $280M | US#493/3,121 Sec#44/205 |
| Per Share | ||
| EPS | $10.50 | US#278/3,121 Sec#18/205 |
| BPS | $45.40 | US#509/3,121 Sec#36/205 |
Company Info
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.